Showcase Your Work
Showcase Your Research & Compete for Poster of the Year
Present your latest findings to a highly targeted audience of oncology drug developers, translational researchers and preclinical decision-makers. Given the focused and intimate nature of the summit, attendees have the opportunity to engage directly with every poster, ask detailed questions and gain meaningful feedback from peers tackling similar modeling challenges.
Why Present a Poster?
- Demonstrate scientific leadership in tumor modeling and translational oncology
- Gain direct feedback from oncology leaders across discovery, translational research, and preclinical development
- Increase visibility among biotech and pharma stakeholders
- Compete for recognition in the Tumor Models Summit Poster Competition
How to Submit Your Poster
- Register to attend the 11th Tumor Models Summit San Francisco
- Submit an abstract outlining your research for review
- You will be notified once your abstract has been accepted along with details of printing and size requirements.
- We do request an online PDF of the poster 2 weeks prior to the summit
- Poster Competition: February 10-11, 2027
- Abstract Submission Deadline: To Be Confirmed
Click the 'Submit Your Poster' button below.
T&Cs:
- Posters should not be used for sales and marketing purposes
- If your company offers pay-for services, you will need to submit your poster request to our partnerships team - sponsor@hansonwade.com
- All abstracts are subject to approval by the conference organizers, who reserve the right to reject submissions
Explore the Full Event Guide
- Explore the full agenda focused on clinical translation, model selection and development risk reduction
- Discover how leading oncology teams are evaluating organoids, ex vivo systems, AI-enabled platforms and in vivo models
- Preview case studies from Amgen, Astellas, Pfizer, Eli Lilly and emerging biotech innovators
- Benchmark approaches to biomarker development, resistance modeling, and candidate prioritization
- Connect with the leaders responsible for oncology development strategy, portfolio decisions, and preclinical investment
